Robeco Institutional Asset Management B.V. decreased its position in Chemed Corp. (NYSE:CHE) by 80.6% during the second quarter, Holdings Channel reports. The firm owned 37,242 shares of the company’s stock after selling 155,042 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Chemed Corp. were worth $5,077,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CHE. BlackRock Inc. boosted its position in Chemed Corp. by 90.4% in the first quarter. BlackRock Inc. now owns 1,152 shares of the company’s stock worth $156,000 after buying an additional 547 shares during the period. C M Bidwell & Associates Ltd. purchased a new position in Chemed Corp. during the first quarter worth approximately $163,000. Magnetar Financial LLC boosted its position in Chemed Corp. by 8.3% in the first quarter. Magnetar Financial LLC now owns 1,914 shares of the company’s stock worth $259,000 after buying an additional 147 shares during the period. Mount Lucas Management LP boosted its position in Chemed Corp. by 10.6% in the first quarter. Mount Lucas Management LP now owns 2,169 shares of the company’s stock worth $294,000 after buying an additional 207 shares during the period. Finally, Capstone Asset Management Co. boosted its position in Chemed Corp. by 17.2% in the second quarter. Capstone Asset Management Co. now owns 2,480 shares of the company’s stock worth $338,000 after buying an additional 364 shares during the period. Institutional investors own 98.62% of the company’s stock.

Shares of Chemed Corp. (NYSE:CHE) traded down 0.41% during mid-day trading on Friday, hitting $139.28. The stock had a trading volume of 209,307 shares. The company’s 50 day moving average price is $138.79 and its 200 day moving average price is $135.01. Chemed Corp. has a 12-month low of $124.77 and a 12-month high of $160.12. The stock has a market cap of $2.25 billion, a P/E ratio of 22.09 and a beta of 1.14.

Chemed Corp. (NYSE:CHE) last released its earnings results on Monday, July 25th. The company reported $1.80 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.72 by $0.08. The firm earned $290 million during the quarter, compared to analysts’ expectations of $393.50 million. Chemed Corp. had a net margin of 6.93% and a return on equity of 24.12%. Chemed Corp.’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.71 EPS. Equities research analysts predict that Chemed Corp. will post $7.25 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 2nd. Shareholders of record on Monday, August 15th were paid a $0.26 dividend. This is a boost from Chemed Corp.’s previous quarterly dividend of $0.24. This represents a $1.04 annualized dividend and a yield of 0.75%. The ex-dividend date of this dividend was Thursday, August 11th. Chemed Corp.’s payout ratio is presently 16.51%.

A number of research firms have commented on CHE. Zacks Investment Research upgraded Chemed Corp. from a “hold” rating to a “buy” rating and set a $167.00 price target on the stock in a research note on Thursday, July 28th. JMP Securities reiterated a “hold” rating on shares of Chemed Corp. in a research note on Sunday, September 4th. RBC Capital Markets reiterated a “sector perform” rating and issued a $162.00 price objective (up from $136.00) on shares of Chemed Corp. in a research note on Wednesday, July 27th. Finally, Royal Bank Of Canada increased their price objective on Chemed Corp. from $136.00 to $162.00 and gave the company a “sector perform” rating in a research note on Wednesday, July 27th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $159.00.

In other Chemed Corp. news, VP Arthur V. Tucker, Jr. sold 3,089 shares of Chemed Corp. stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $143.88, for a total value of $444,445.32. Following the completion of the sale, the vice president now directly owns 3,234 shares of the company’s stock, valued at approximately $465,307.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Donald E. Saunders sold 500 shares of Chemed Corp. stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $144.32, for a total transaction of $72,160.00. Following the completion of the sale, the director now directly owns 10,786 shares of the company’s stock, valued at $1,556,635.52. The disclosure for this sale can be found here. 5.32% of the stock is currently owned by company insiders.

Chemed Corp. Company Profile

Chemed Corporation operates and divests subsidiaries engaged in diverse business activities. The Company operates its business in two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS segment provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

5 Day Chart for NYSE:CHE

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corp. (NYSE:CHE).

Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.